FutureChem shares are surging in the early part of the trading session on the 10th. This is due to the announcement of the results of the Phase 3 clinical trial for the prostate cancer diagnostic radiopharmaceutical "FC303."
As of 9:16 a.m. on that day, FutureChem shares were trading at 20,050 won, up 13.79% (2,430 won) from the previous trading day in the KOSDAQ market.
Earlier, FutureChem announced through a public disclosure that it had received the final report on the Phase 3 clinical results for the prostate cancer diagnostic radiopharmaceutical "FC303."
According to the company, the positive predictive value of the imaging examination for FC303 was 86.96%. Notably, the lower bound of the 95% confidence interval was 79.01%, exceeding the benchmark of 60.6%, indicating clinical efficacy.